FDA tone is everywhere - and the system cannot pick a side, so neither should you
The Opportunity
The upstream output explicitly marks this as MIXED direction despite a tradeable proxy (IHE/XBI), which is a useful intelligence result in itself: the system cannot resolve whether the dominant FDA signal is loosening (bullish) or tightening (bearish) in a way that cleanly maps to equities.
The Timing
This is AVOID because it sits in edge-decay and direction is MIXED. What would change that is a single, concrete policy artefact with an implementation timeline that clearly shifts approval burden in a named product class. Until then, the 'FDA tone' story will be endlessly tradable as chatter and rarely tradable as edge.
The Evidence
Upstream shows Tier-1 presence and high propagation, which is the opposite of informational advantage. No hydrated evidence links are present in this run. The correct reading is that this is a crowded macro narrative with insufficient mechanism resolution to justify a directional proxy position.